Last updated: April 23, 2026
Which companies supply terbinafine hydrochloride (API) to pharma and contract manufacturers?
Terbinafine hydrochloride is an established generic active pharmaceutical ingredient (API) supplied through a mix of large Asian API producers, specialty ingredient firms, and global distributors. For sourcing and supply-chain mapping, companies typically fall into three buckets: (1) API manufacturers that sell directly or via distributors, (2) contract manufacturing organizations (CMOs) that source the API as inbound raw material, and (3) global trading/distribution channels that supply API and intermediates under commercial supply agreements.
Representative API and ingredient suppliers (terbinafine hydrochloride / terbinafine-based actives)
The most actionable way to build supplier shortlists for terbinafine hydrochloride is to start with firms that (a) publicly market terbinafine hydrochloride as an API or API-grade ingredient and (b) support regulated supply (DMF/CEP filings or audits via standard qualification processes). A supplier mapping that matches real-world procurement behavior typically includes the following named companies:
| Supplier (company) |
Supplier type |
What they typically provide in the terbinafine supply chain |
| Alkem Laboratories (India) |
API and pharma manufacturer |
Terbinafine-related API and/or finished-generic production capacity via regulated manufacturing networks |
| Aurobindo Pharma (India) |
API and pharma manufacturer |
Generic API supply, including established dermatology molecules |
| Cipla (India) |
Pharma manufacturer |
Terbinafine supply via regulatory manufacturing for generic products; API sourcing through internal networks or contracted API procurement |
| Hetero Drugs (India) |
Pharma manufacturer |
Terbinafine product supply; API procurement from qualified upstream sources |
| Intas Pharmaceuticals (India) |
Pharma manufacturer |
Dermatology/generic supply; API sourcing through qualified supply chain |
| Sun Pharma (India) |
Pharma manufacturer |
Established generic dermatology molecule supply through qualified upstream sourcing |
| Torrent Pharmaceuticals (India) |
Pharma manufacturer |
Terbinafine generic supply; upstream sourcing through qualified API network |
| Mylan (formerly Viatris) (global) |
Pharma manufacturer |
Terbinafine generic supply in regulated markets; upstream API sourcing through qualified channels |
| Hikma Pharmaceuticals (global) |
Pharma manufacturer |
Terbinafine product supply into regulated markets via qualified supply chain |
| Amneal Pharmaceuticals (global) |
Pharma manufacturer |
Terbinafine product supply into regulated markets via qualified upstream sourcing |
How to use this list for procurement: start with companies that produce or sell the API under their own regulated manufacturing programs (API producers and API-capable pharma manufacturers), then expand via distribution channels to guarantee lead-time coverage and batch diversity.
What supplier categories matter most for qualification and continuity of supply?
Terbinafine hydrochloride procurement is usually constrained by (1) raw-material availability for upstream steps, (2) audit readiness (GMP status and quality system maturity), and (3) documentation completeness (DMF/CEP readiness, CoA format, stability package). The following supplier categories dominate what buyers qualify:
-
API manufacturers with established DMF/regulated filings
- Best for: direct API purchase, stable documentation flow, predictable batch-to-batch consistency.
- Typical buyer action: request DMF/ASMF references, CoA samples, impurity profile comparability package.
-
Large generic pharma with integrated upstream sourcing
- Best for: consistent commercial supply, batch record governance, change control discipline.
- Typical buyer action: treat as “commercial API-to-finished channel,” then confirm API sourcing and spec coverage.
-
Global API distributors
- Best for: fast qualification of alternates, short-term volume coverage.
- Typical buyer action: qualify distributor as a logistics/traceability channel plus the actual API manufacturer behind the supply.
Where does the terbinafine hydrochloride supply base concentrate geographically?
Demand and supply for terbinafine hydrochloride concentrate in mature generic manufacturing ecosystems, with supplier activity strongly represented in:
- India (large API and generic manufacturing footprint)
- China (large-scale API production base that supplies global distributors and contract manufacturers)
- Europe and North America (more frequently act as pharma product manufacturers and distribution hubs than primary API manufacturing, but still influence upstream qualification)
How should buyers structure supplier shortlists for terbinafine hydrochloride?
A practical shortlisting approach for regulated API sourcing usually uses these selection criteria:
- Regulatory documentation readiness: DMF/ASMF availability or equivalent dossier coverage; ability to provide full spec and impurity profile
- GMP manufacturing footprint: audited manufacturing site approvals and capacity to meet your batch size
- Specification alignment: identity, assay, residual solvents, water content where relevant, impurity limits and degradants
- Supply continuity: multi-year commercial supply history and ability to offer alternate manufacturing routes/sites
What are the key product forms and specs that influence supplier selection?
Suppliers may market terbinafine hydrochloride across multiple grades and intended uses (API vs intermediate, or different pharmacopeial alignment). Buyers should map supplier offerings to:
- API grade suitable for oral or topical finished dosage forms
- Particle form / polymorph control (where available from the supplier’s quality package)
- Impurity control aligned with your finished-product impurity acceptance strategy
What due-diligence artifacts matter in terbinafine hydrochloride supplier qualification?
Procurement teams typically require:
- Certificate of Analysis (CoA) for at least one or more recent batches (to verify assay and impurity acceptance)
- Specification sheet covering identity, assay, impurities, residual solvents, and moisture content where applicable
- Stability support: at minimum supplier-provided data if you integrate it into your drug substance method lifecycle
- Change control disclosures: site, process, or specification changes and their comparability statements
Who should be on a procurement “first call” list for terbinafine hydrochloride?
A first-call supplier set typically includes:
- 2 to 4 API-capable manufacturers (direct)
- 1 to 2 global distributors for alternate lead-time coverage
- 1 backup API manufacturer qualified through a secondary channel (to avoid single-source dependency)
The company set above (Alkem, Aurobindo, Cipla, Hetero, Intas, Sun Pharma, Torrent, plus global generics like Mylan/Viatris, Hikma, and Amneal) represents the kind of regulated supply ecosystem buyers routinely use to source terbinafine-related actives and finished generic products.
Key Takeaways
- Terbinafine hydrochloride supply is dominated by established generic manufacturing networks, with India and China as central upstream regions and Europe/North America as strong downstream regulated generic markets.
- Procurement success depends on qualifying suppliers on dossier readiness, GMP manufacturing governance, and impurity/spec alignment, not just commercial price.
- Build a shortlist with API-capable manufacturers first, then add global distributors and a backup manufacturer to protect continuity.
FAQs
1) Are terbinafine hydrochloride suppliers mostly API manufacturers or pharma companies?
In practice, buyers source through both. API-capable manufacturers sell the drug substance directly, while large generic pharma companies also influence supply through internal sourcing and regulated distribution to finished-product channels.
2) What documentation do buyers typically request for terbinafine hydrochloride?
CoA, full specification (including impurity limits), identity and assay methods references, and stability support. If the supplier operates in regulated markets, DMF/ASMF or equivalent quality dossier references are typically part of qualification.
3) Which regions have the largest terbinafine hydrochloride supplier footprint?
The supplier footprint concentrates in India and China due to scale of generic API manufacturing, with regulatory downstream markets in Europe and North America.
4) How many suppliers should be qualified for continuity?
A practical structure is 2 to 4 primary qualified suppliers plus 1 backup supplier, with at least one alternate channel to avoid single-source disruption.
5) What is the biggest supplier qualification risk for terbinafine hydrochloride?
Spec and impurity profile alignment across batches and process changes, especially when changing manufacturing sites or upstream input suppliers.
References
[1] European Medicines Agency (EMA). Community Register of medicinal products and related information for active substances.
[2] FDA Drug Products and related databases (Orange Book and product listings for terbinafine-containing medicines).
[3] USP/NF and pharmacopoeial monographs relevant to terbinafine hydrochloride specifications.
[4] Company websites and corporate manufacturing/distribution disclosures for major generic manufacturers listed above.
